Local immunological mechanisms of sublingual immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 6, 2011, Pages 571-578

  Allam, Jean Pierre ^a   Novak, Natalija ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

dendritic cells; immunotherapy; oral mucosa; sublingual; Th1; Th2; tolerance

Indexed keywords

ALLERGEN; GRASS POLLEN EXTRACT;

ANTIGEN PRESENTING CELL; BRONCHUS MUCOSA; CELLULAR IMMUNITY; CLINICAL FEATURE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; INTERMETHOD COMPARISON; MEDICAL RESEARCH; MOUTH MUCOSA; NONHUMAN; ORAL IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE ACTIVATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; ANTIGEN PRESENTATION; DENDRITIC CELLS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; MICE; MOUTH MUCOSA; T-LYMPHOCYTES;

EID: 80255127499     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32834cbaab     Document Type: Review

References (67)

1. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011; 66:740-752.
2. Calderon MA, Boyle RJ, Penagos M, Sheikh A. Immunotherapy: the metaanalyses: what have we Learned? Immunol Allergy Clin North Am 2011; 31:159-173; vii.
3. Calderon MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011; 127:30-38.
4. Valovirta E, Passalacqua G, Canonica WG. Noninjection routes for immunotherapy of allergic diseases. Clin Allergy Immunol 2004; 18:607-623.
5. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4-12.
6. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011; 66:725-732.
7. Novak N, Bieber T, Allam JP. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy 2011; 66:733-739.
8. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127:18-27.
9. Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends Mol Med 2008; 14:191-198.
10. Chehade M, Mayer L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 2005; 115:3-12; quiz 13.
11. Brandtzaeg P, Pabst R. Lets go mucosal: communication on slippery ground. Trends Immunol 2004; 25:570-577.
12. Jotwani R, Palucka AK, Al-Quotub M, et al. Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. J Immunol 2001; 167:4693-4700.
13. Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 2009; 70:505-515.
14. Kelsall B. Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages. Mucosal Immunol 2008; 1:460-469.
15. Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003; 171:6323-6327.
16. Kelsall BL. Innate and adaptive mechanisms to control [corrected] pathological intestinal inflammation. J Pathol 2008; 214:242-259.
17. Novak N, Allam JP. Mucosal dendritic cells in allergy and immunotherapy. Allergy 2011; 66 (Suppl 95):22-24.
18. Allam JP, Duan Y, Winter J, et al. Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites. Allergy 2011; 66:532-539.
19. Mascarell L, Lombardi V, Zimmer A, et al. Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4+ T cells. Clin Exp Allergy 2009; 39:1910-1919.
20. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007; 117:1119-1127.
21. Blaschitz C, Raffatellu M. Th17 cytokines and the gut mucosal barrier. J Clin Immunol 2010; 30:196-203.
22. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-426.
23. Novak N, Gros E, Bieber T, Allam JP. Human skin and oral mucosal dendritic cells as good guys and bad guys in allergic immune responses. Clin Exp Immunol 2010; 161:28-33.
24. Romani N, Clausen BE, Stoitzner P. Langerhans cells and more: langerinexpressing dendritic cell subsets in the skin. Immunol Rev 2010; 234:120-141.
25. Valladeau J, Ravel O, Dezutter-Dambuyant C, et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000; 12:71-81.
26. Charbonnier AS, Kohrgruber N, Kriehuber E, et al. Macrophage inflammatory protein 3alpha is involved in the constitutive trafficking of epidermal Langerhans cells. J Exp Med 1999; 190:1755-1768.
27. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23:445-449.
28. Mascarell L, Lombardi V, Louise A, et al. Oral dendritic cells mediate antigenspecific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008; 122:603 e605-609 e605.
29. Lombardi V, Van Overtvelt L, Horiot S, et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 2008; 38:1819-1829.
30. Mascarell L, Saint-Lu N, Moussu H, et al., Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal Immunol (in press).
31. Allam JP, Niederhagen B, Bucheler M, et al. Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 2006; 61:166-172.
32. Allam JP, Novak N, Fuchs C, et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003; 112:141-148.
33. Allam JP, Peng WM, Appel T, et al., Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121:368.e1-374.e1.
34. Allam JP, Bieber T, Novak N. Dendritic cells as potential targets for mucosal immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9:554-557.
35. Allam JP, Klein E, Bieber T, Novak N. Transforming growth factor-beta1 regulates the expression of the high-affinity receptor for IgE on CD34 stem cell-derived CD1a dendritic cells in vitro. J Invest Dermatol 2004; 123:676-682.
36. Allam JP, Wurtzen PA, Reinartz M, et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta 1 and IL-10-producing properties. J Allergy Clin Immunol 2010; 126:638-645.
37. Allam JP, Stojanovski G, Friedrichs N, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 2008; 63:720-727.
38. Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.
39. Demoly P, Calderon MA. Dosing and efficacy in specific immunotherapy. Allergy 2011; 66 (Suppl 95):38-40.
40. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-809.
41. Kildsgaard J, Brimnes J, Jacobi H, Lund K. Sublingual immunotherapy in sensitized mice. Ann Allergy Asthma Immunol 2007; 98:366-372.
42. Rask C, Brimnes J, Lund K. Shorter dosing intervals of sublingual immunotherapy lead to more efficacious treatment in a mouse model of allergic inflammation. Scand J Immunol 2010; 71:403-412.
43. Razafindratsita A, Saint-Lu N, Mascarell L, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007; 120:278-285.
44. Saint-Lu N, Tourdot S, Razafindratsita A, et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 2009; 64:1003-1013.
45. Pfaar O, Barth C, Jaschke C, et al. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2011; 154:336-344.
46. Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:507-514.
47. Marcucci F, Incorvaia C, Sensi L, et al. Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol 2008; 21:609-614.
48. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121:1467-1472; 1472.e1.
49. Wilson DR, Irani AM, Walker SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31:1705-1713.
50. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration ofCD4+T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-1365.
51. Passalacqua G, Albano M, Riccio A, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:964-968.
52. Marogna M, Spadolini I, Massolo A, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005; 115:1184-1188.
53. Bahceciler NN, Arikan C, Taylor A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136:287-294.
54. Kaminuma O, Suzuki K, Mori A. Effect of sublingual immunotherapy on antigen-induced bronchial and nasal inflammation in mice. Int Arch Allergy Immunol 2010; 152 (Suppl 1):75-78.
55. Brimnes J, Kildsgaard J, Jacobi H, Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy 2007; 37:488-497.
56. Yu HQ, Li XH, Guo H, et al. Sublingual immunotherapy efficacy of Dermatophagoides farinae vaccine in a murine asthma model. Int Arch Allergy Immunol 2010; 152:41-48.
57. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-713.
58. OHehir RE, Gardner LM, de Leon MP, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009; 180:936-947.
59. Nieminen K, Valovirta E, Savolainen J. Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollenallergic children during sublingual immunotherapy. Pediatr Allergy Immunol 2010; 21:e174-e184.
60. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006; 61:1184-1190.
61. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin- 10-production. Clin Exp Allergy 2006; 36:261-272.
62. Bussmann C, Xia J, Allam JP, et al. Early markers for protective mechanisms during rush venom immunotherapy. Allergy 2010; 65:1558-1565.
63. Dehlink E, Eiwegger T, Gerstmayr M, et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006; 36:32-39.
64. Rolinck-Werninghaus C, Kopp M, Liebke C, et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005; 136:134-141.
65. Dahl R, Kapp A, Colombo G, et al., Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:512.e2-518.e2.
66. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131-138; e131-e137.
67. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of oncedaily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-1345.